Equities Analysts Set Expectations for ATXS Q3 Earnings

Astria Therapeutics, Inc. (NASDAQ:ATXS) – Investment analysts at HC Wainwright upped their Q3 2025 earnings per share (EPS) estimates for Astria Therapeutics in a report issued on Wednesday, August 13th. HC Wainwright analyst J. Pantginis now anticipates that the biotechnology company will earn ($0.66) per share for the quarter, up from their prior forecast of ($0.69). HC Wainwright has a “Buy” rating and a $16.00 price target on the stock. The consensus estimate for Astria Therapeutics’ current full-year earnings is ($1.65) per share. HC Wainwright also issued estimates for Astria Therapeutics’ Q4 2025 earnings at ($0.71) EPS and FY2025 earnings at ($2.53) EPS.

A number of other research analysts also recently issued reports on ATXS. Citigroup reissued an “outperform” rating on shares of Astria Therapeutics in a report on Wednesday. JMP Securities boosted their price target on Astria Therapeutics from $25.00 to $26.00 and gave the company a “market outperform” rating in a report on Wednesday. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $47.00 target price on shares of Astria Therapeutics in a research note on Wednesday, May 14th. Six investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, Astria Therapeutics presently has a consensus rating of “Buy” and a consensus price target of $29.00.

Astria Therapeutics Trading Up 1.3%

Shares of NASDAQ:ATXS opened at $6.85 on Friday. Astria Therapeutics has a 12-month low of $3.56 and a 12-month high of $12.92. The company has a market capitalization of $386.61 million, a PE ratio of -3.41 and a beta of 0.48. The business has a 50 day moving average of $6.23 and a two-hundred day moving average of $5.76.

Astria Therapeutics (NASDAQ:ATXS) last issued its earnings results on Tuesday, August 12th. The biotechnology company reported ($0.57) EPS for the quarter, beating analysts’ consensus estimates of ($0.61) by $0.04.

Institutional Trading of Astria Therapeutics

Several large investors have recently added to or reduced their stakes in ATXS. JPMorgan Chase & Co. grew its holdings in Astria Therapeutics by 39.6% in the 4th quarter. JPMorgan Chase & Co. now owns 54,664 shares of the biotechnology company’s stock valued at $489,000 after buying an additional 15,520 shares in the last quarter. Wells Fargo & Company MN grew its holdings in shares of Astria Therapeutics by 47.3% during the 4th quarter. Wells Fargo & Company MN now owns 23,569 shares of the biotechnology company’s stock worth $211,000 after purchasing an additional 7,563 shares during the period. Legal & General Group Plc grew its holdings in shares of Astria Therapeutics by 7.6% during the 4th quarter. Legal & General Group Plc now owns 31,418 shares of the biotechnology company’s stock worth $281,000 after purchasing an additional 2,222 shares during the period. Raymond James Financial Inc. purchased a new position in shares of Astria Therapeutics during the 4th quarter worth $707,000. Finally, Barclays PLC grew its holdings in shares of Astria Therapeutics by 5.6% during the 4th quarter. Barclays PLC now owns 97,820 shares of the biotechnology company’s stock worth $875,000 after purchasing an additional 5,169 shares during the period. 98.98% of the stock is currently owned by hedge funds and other institutional investors.

Astria Therapeutics Company Profile

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.